Tech Company Financing Transactions

Kemia Funding Round

Kemia, based in San Diego, secured $33.5 million from JPMorgan Partners, Alta Partners and Forward Ventures.

Transaction Overview

Company Name
Announced On
3/29/2004
Transaction Type
Venture Equity
Amount
$33,500,000
Round
Series B
Investors

JPMorgan Partners (Lead Investor) (Rod Ferguson)

Alta Partners (Daniel Janney)

Forward Ventures (Standish Fleming)

Novartis BioVenture Fund

Novo Ventures

TPG Capital (Fred Cohen)

Proceeds Purpose
Kémia's first drug candidate, an allosteric kinase inhibitor for inflammation, is projected to begin human clinical trials early in 2005.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
5871 Oberlin Drive 100
San Diego, CA 92121
USA
Email Address
Overview
Kémia discovers and develops novel small molecule therapeutics. Kémia focuses on high value disease targets that are validated, but not yet addressed by safe and effective non-injectable drugs.
Profile
Kemia LinkedIn Company Profile
Social Media
Kemia Company Twitter Account
Company News
Kemia News
Facebook
Kemia on Facebook
YouTube
Kemia on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Lewis Shuster
  Lewis Shuster LinkedIn Profile  Lewis Shuster Twitter Account  Lewis Shuster News  Lewis Shuster on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/29/2004: Fluency Voice Technology venture capital transaction
Next: 3/30/2004: Mendocino Software venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary